title: Reduced adhesion of PBMNCs to endothelium in methylprednisolone-treated MS patients: preliminary results.
abstract: Methylprednisolone (MP) is a synthetic steroid commonly used in the treatment of multiple sclerosis (MS) relapses. It has a wide spectrum of activities on immune cells: it might also act by preventing mononuclear cell/endothelium adhesion. We studied adhesion phenomena between cultured human umbilical vein endothelial cells (HUVECs) and PBMNCs (CD45+, CD14+) from 6 MS patients treated in vivo with MP. We also studied fluctuations in CD11a and CD18 levels on lymphocytes and monocytes, as well as changes in serum sICAM-1 and sVCAM-1 concentrations. After MP treatment, PBMNCs adhesion to endothelium decreased at 3 h, while it went back to baseline levels at 24 h. A tendency to increase in both CD11a and CD18 on the surface of lymphocytes was detected, while an increase in serum sVCAM-1 was seen at 3 h.
authors.affiliation: Istituto Nazionale Neurologico C. Besta, Milan, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Gelati
authors.forename: E
authors.initials: E
authors.lastname: Corsini
authors.forename: A
authors.initials: A
authors.lastname: Dufour
authors.forename: E
authors.initials: E
authors.lastname: Ciusani
authors.forename: G
authors.initials: G
authors.lastname: Massa
authors.forename: S
authors.initials: S
authors.lastname: Frigerio
authors.forename: C
authors.initials: C
authors.lastname: Milanese
authors.forename: A
authors.initials: A
authors.lastname: Nespolo
authors.forename: A
authors.initials: A
authors.lastname: Salmaggi
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D018821:CD18 Antigens / Q000097:blood; D002448:Cell Adhesion / Q000187:drug effects* / Q000276:immunology; D002478:Cells, Cultured; D018450:Disease Progression; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000276:immunology; D005260:Female; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D017493:Leukocyte Common Antigens / Q000097:blood; D018950:Lipopolysaccharide Receptors / Q000097:blood; D016169:Lymphocyte Function-Associated Antigen-1 / Q000097:blood; D016131:Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects* / Q000276:immunology; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology; D019010:Vascular Cell Adhesion Molecule-1 / Q000097:blood
chemical_list: D000893:Anti-Inflammatory Agents; D018821:CD18 Antigens; D018950:Lipopolysaccharide Receptors; D016169:Lymphocyte Function-Associated Antigen-1; D019010:Vascular Cell Adhesion Molecule-1; D018799:Intercellular Adhesion Molecule-1; D017493:Leukocyte Common Antigens; D008775:Methylprednisolone